Core Viewpoint - Xianju Pharmaceutical has received approval from the National Medical Products Administration for its Acetate Dexamethasone Tablets, indicating successful consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The company announced the receipt of the approval notice for the drug supplement application for Acetate Dexamethasone Tablets [1] - The approval notice is identified by the number 2025B03820 [1] - The drug has passed the consistency evaluation for quality and efficacy as a generic medication [1]

醋酸地塞米松片为肾上腺皮质激素类药，主要用于过敏性与自身免疫性炎症性疾病。如结缔组织病，严 重的支气管哮喘，皮炎等过敏性疾病，溃疡性结肠炎，急性白血病，恶性淋巴瘤等。 格隆汇8月22日丨仙琚制药(002332.SZ)公布，公司于近日收到国家药品监督管理局核准签发的关于醋酸 地塞米松片的《药品补充申请批准通知书》(通知书编号：2025B03820)，公司醋酸地塞米松片通过仿制 药质量和疗效一致性评价。 ...

Core Viewpoint - Xianju Pharmaceutical (002332) has received approval from the National Medical Products Administration for its Acetate Dexamethasone Tablets, which have passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1: Company Information - The Acetate Dexamethasone Tablets are classified as adrenal cortex hormones and are primarily used for allergic and autoimmune inflammatory diseases [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for its dexamethasone acetate tablets, which have passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1: Company Information - The dexamethasone acetate tablets are classified as corticosteroids and are primarily used for allergic and autoimmune inflammatory diseases such as connective tissue diseases, severe bronchial asthma, dermatitis, ulcerative colitis, acute leukemia, and malignant lymphoma [1]

证券代码：002332 证券简称：仙琚制药 公告编号：2025-033 申请内容：申报仿制药质量和疗效一致性评价。 审批结论：根据《中华人民共和国药品管理法》、《国务院关于改革药 品医疗器械审评审批制度的意见》（国发〔2015〕44号）和《关于仿制药质 量和疗效一致性评价工作有关事项的公告》（2017年第100号）的规定，经审 查，本品视同通过仿制药质量和疗效一致性评价。 二、药品的其他相关情况 醋酸地塞米松片为肾上腺皮质激素类药，主要用于过敏性与自身免疫性 炎症性疾病。如结缔组织病，严重的支气管哮喘，皮炎等过敏性疾病，溃疡 性结肠炎，急性白血病，恶性淋巴瘤等。 浙江仙琚制药股份有限公司 关于醋酸地塞米松片通过一致性评价的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 浙江仙琚制药股份有限公司（以下简称"公司"）于近日收到国家药品 监督管理局核准签发的关于醋酸地塞米松片的《药品补充申请批准通知书》 （通知书编号：2025B03820），公司醋酸地塞米松片通过仿制药质量和疗效 一致性评价。现将相关情况公告如下： | 药品名称 | 剂型 | 规格 | 药品注 ...

Group 1 - The core viewpoint of the report is that Huazhong Securities has given a "buy" rating for Xianju Pharmaceutical (002332.SZ) based on its strong position in the steroid hormone sector and integrated layout of raw materials and formulations [2] - The raw material business has seen an end to customer destocking, leading to a recovery in demand [2] - Risks associated with centralized procurement of formulations have gradually cleared, and new products are being approved and released [2]

证券之星消息，8月21日化学制药板块较上一交易日上涨0.09%，*ST苏吴领涨。当日上证指数报收于 3771.1，上涨0.13%。深证成指报收于11919.76，下跌0.06%。化学制药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 600200 | *ST苏吴 | 0.96 | 5.49% | 43.67万 | | 4141.60万 | | 300705 | 九典制药 | 19.87 | 4.97% | 52.35万 | | 10.35 Z | | 300573 | 兴齐眼药 | 67.48 | 4.69% | 22.77万 | | 15.19 Z | | 688506 | 百利天恒 | 324.96 | 4.21% | 1.62万 | | 5.23亿 | | 002940 | 昂利康 | 51.36 | 3.86% | 15.16万 | | 7.69亿 | | 002020 | 京新药业 | 19.52 | 2.90% | 32.05万 | | 6.16 ...

Group 1 - The chemical pharmaceutical sector increased by 2.34% on August 13, with Shouyao Holdings leading the gains [1] - The Shanghai Composite Index closed at 3683.46, up 0.48%, while the Shenzhen Component Index closed at 11551.36, up 1.76% [1] - Notable gainers in the chemical pharmaceutical sector included Shouyao Holdings, which rose by 19.99% to a closing price of 55.94, and Weichip Bio, which increased by 14.39% to 41.18 [1] Group 2 - The chemical pharmaceutical sector saw a net inflow of 342 million yuan from main funds, while retail investors contributed a net inflow of 426 million yuan [2] - Major stocks with significant net inflows included Heng Rui Pharmaceutical with 55.1 million yuan and Fu Xing Pharmaceutical with 23.4 million yuan [3] - Conversely, stocks like ST Sailong and ST Suwu experienced notable net outflows of 4.97% and 3.70%, respectively [2]

仙琚制药最新一期业绩显示，截至2025一季报，公司营业总收入10.08亿元、同比减少2.86%，归属净利 润1.44亿元，同比减少4.72%，扣非净利润1.44亿元，同比减少0.76%，流动比率4.642、速动比率 3.355、资产负债率14.80%。 天眼查商业履历信息显示，浙江仙琚制药股份有限公司，成立于2000年，位于台州市，是一家以从事医 药制造业为主的企业。企业注册资本98920.4866万人民币，实缴资本98920.4866万人民币。公司法定代 表人为张宇松。 通过天眼查大数据分析，浙江仙琚制药股份有限公司共对外投资了33家企业，参与招投标项目5000次， 知识产权方面有商标信息203条，专利信息110条，此外企业还拥有行政许可257个。 来源：金融界 金融界消息 截至2025年8月13日收盘，仙琚制药（002332）报收于11.58元，上涨7.82%，换手率 10.91%，成交量107.46万手，成交金额12.16亿元。 资金流向方面，今日主力资金净流入6408.93万元，占比成交额5.27%。其中，超大单净流入6762.29万 元、占成交额5.56%，大单净流出353.36万元、占成交额0.2 ...

Core Viewpoint - The National Market Supervision Administration of China has imposed administrative penalties on four pharmaceutical companies for engaging in a monopoly agreement, resulting in a total fine exceeding 362 million yuan [1][2]. Group 1: Companies Involved - The companies involved in the monopoly agreement are Tianjin Pharmaceutical Industry Co., Ltd. (津药药业), Zhejiang Xianju Pharmaceutical Co., Ltd. (仙琚制药), Jiangsu Lianhuan Pharmaceutical Co., Ltd. (联环药业), and Xi'an Guokang Ruijin Pharmaceutical Co., Ltd. (国康瑞金制药) [1]. - Among these, Lianhuan Pharmaceutical, Tianjin Pharmaceutical, and Xianju Pharmaceutical hold the approval for the injection of dexamethasone phosphate sodium and have undergone consistency evaluation [2]. Group 2: Penalties and Financial Impact - The total fines imposed include 500,000 yuan on the individual responsible, confiscation of illegal gains, and an 8% fine on the previous year's sales for the four companies, amounting to approximately 355 million yuan [2]. - For Lianhuan Pharmaceutical, the penalty represents 2.83% of the company's audited revenue and 72.53% of the net profit attributable to shareholders for the most recent fiscal year [2]. - The penalty will reduce the net profit attributable to shareholders for Lianhuan Pharmaceutical by approximately 61.0382 million yuan for the fiscal year 2025 [2]. Group 3: Market Impact - The companies coordinated to raise the price of dexamethasone phosphate sodium from 8,000 yuan per kilogram to 13,000 yuan between February 2022 and March 2024, significantly restricting market competition and increasing healthcare costs for consumers [1].